SCHEMBL4816619

SCHEMBL4816619

Clc1ccc(-c2[c]nccc2)cn1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.53
PIK3CD O00329 1/20 0.43
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
NOTUM Q6P988 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.34
CHRNB2 P17787 5/20 0.34
CHRNA4 P43681 4/20 0.34
CHRNA3 P32297 3/20 0.34
CHRNA7 P36544 3/20 0.34
CHRNB4 P30926 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412002 0.77 NOTUM (0.39) CYP2A6NPC1RAB9ANOTUMKDM4E
SCHEMBL4489657 0.73 CYP2A6 (0.56) CYP2A6KDM4EALDH1A1MEN1
SCHEMBL4810970 0.73 AHR (0.46) NPC1RAB9ANOTUMKDM4EALDH1A1
SCHEMBL3741986 0.73 CYP2A6 (0.46) CYP2A6PIK3CDNPC1RAB9ANOTUM
SCHEMBL1662273 0.71 PIK3CD (0.73) CYP2A6PIK3CDNPC1RAB9ANOTUM
SCHEMBL4909130 0.71
SCHEMBL19439 0.70 NOTUM (0.39) CYP2A6NPC1RAB9ANOTUMALDH1A1
SCHEMBL1742451 0.69 CYP2A6 (1.00) CYP2A6PIK3CDNPC1RAB9AKDM4E
SCHEMBL4590846 0.69 MAPK14 (0.35) NPC1RAB9AALDH1A1KMT2A
SCHEMBL4808978 0.69 NOTUM (0.43) NPC1RAB9ANOTUMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329660-B2 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2008-02-12 US disclosed
US-20060217388-A1 Phthalazine derivatives for treating inflammatory diseases BOLD GUIDO 2006-09-28 US disclosed
EP-1165085-B1 PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES NOVARTIS AG (CH) 2006-06-14 EP disclosed
US-6911440-B2 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2005-06-28 US disclosed
US-20030013718-A1 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013718-A1 Phthalazine derivatives for treating inflammatory diseases FLT1, KDR, FFAR2 CYP2A6 1209/4885PIK3CD 1595/4885NPC1 2209/4885
US-20060217388-A1 Phthalazine derivatives for treating inflammatory diseases KDR, NR2E3, FLT1 CYP2A6 3459/4885PIK3CD 709/4885NPC1 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.